Breaking News Instant updates and real-time market news.

NIO

NIO Inc.

$2.07

0.13 (6.72%)

, GME

GameStop

$6.03

0.365 (6.45%)

08:45
11/26/19
11/26
08:45
11/26/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: NIO (NIO) 86.67% +0.75, GameStop (GME) 32.60% +0.57, Direxion Daily Semiconductor Bull 3X Shares (SOXL) 2.15% +0.30, ADT (ADT) 27.27% +0.18, Fitbit (FIT) 0.43% +0.15, Frontier Communications (FTR) 98.85% +0.14, JinkoSolar (JKS) 0.69% +0.08, Nike (NKE) 0.55% +0.05, Tilray (TLRY) 87.66% +0.05, and iShares DJ US Real Estate Index Fund (IYR) 0.48% +0.04.

NIO

NIO Inc.

$2.07

0.13 (6.72%)

GME

GameStop

$6.03

0.365 (6.45%)

ADT

ADT Inc.

$9.16

0.465 (5.35%)

FIT

Fitbit

$6.78

-0.075 (-1.09%)

FTR

Frontier Communications

$0.69

0.024 (3.61%)

JKS

JinkoSolar

$16.93

-0.395 (-2.28%)

NKE

Nike

$92.94

-0.4 (-0.43%)

TLRY

Tilray

$20.78

-0.525 (-2.46%)

IYR

DJ US Real Estate Index Fund

$92.04

0.33 (0.36%)

  • 10

    Dec

  • 10

    Dec

  • 13

    Dec

NIO NIO Inc.
$2.07

0.13 (6.72%)

10/04/19
10/04/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. HP Inc. (HPQ) downgraded to Hold from Buy at Loop Capital with analyst Ananda Baruah citing HP's Analyst Day presentation disclosing strategic initiatives, job cuts, and a free cash flow guide of $3B in FY20 vs. $3.7B in FY21. 2. Insulet (PODD) downgraded to Neutral from Buy at UBS with analyst Matthew Taylor citing valuation. 3. NIO Inc. (NIO) downgraded to Neutral from Buy at Goldman Sachs with analyst Fei Fang saying Nio's share price has fallen 40% since September 24, when the company announced Q2 results, which Fang attributes to uncertainties about volume since Chinese EV sales have rapidly declined after the government reduced electric vehicle subsidies and about the company's capital structure and funding needs. 4. EchoStar (SATS) downgraded to Neutral from Buy at Citi with analyst Michael Rollins saying the company's lack of free cash flow and limited visibility on its future growth prospects will likely limit the potential for multiple expansion. 5. Ambarella (AMBA) resumed with a Hold from Buy at Stifel with analyst Tore Svanberg saying he believes inventory build in security surveillance, especially China, could limit near term upside in the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/04/19
GSCO
10/04/19
DOWNGRADE
Target $1.47
GSCO
Neutral
Goldman Sachs downgrades NIO Inc. to Neutral, slashes target to $1.47 from $9.76
Goldman Sachs analyst Fei Fang downgraded NIO Inc. to Neutral from Buy with a price target of $1.47, down from $9.76. Nio's share price has fallen 40% since September 24, when the company announced Q2 results, which Fang attributes to uncertainties about volume since Chinese EV sales have rapidly declined after the government reduced electric vehicle subsidies and about the company's capital structure and funding needs. Fang maintains a 2023 estimate of the total addressable market for EVs in China of 1M new car sales, but lowered Nio's 2023 market share forecast to 15% from 25% due to more intense EV competition.
10/04/19
GSCO
10/04/19
DOWNGRADE
GSCO
Neutral
NIO Inc. downgraded to Neutral from Buy at Goldman Sachs
09/26/19
WOLF
09/26/19
DOWNGRADE
Target $1.9
WOLF
Peer Perform
NIO Inc. downgraded to Peer Perform from Outperform at Wolfe Research
Wolfe Research analyst Dan Galves downgraded NIO Inc. to Peer Perform from Outperform, stating that the company's cash burn was worse than expected in Q2 and its volume and margin guidance was "disappointing." The company's financing outlook has become "completely unclear" and the lack of a financing announcement along with earnings is "concerning," said the analyst, who set a $1.90 price target on the stock.
GME GameStop
$6.03

0.365 (6.45%)

09/11/19
BARD
09/11/19
NO CHANGE
Target $6
BARD
Neutral
GameStop strategy updated but headwinds remain, says Baird
Baird analyst Peter Benedict noted GameStop reported another disappointing quarter but said management outlines a new strategy to improve profitability and drive deeper customer engagement. The analyst believes despite the new focus, the near-term impact of an eroding console cycle is likely to more than offset any material improvements. Benedict maintained his Neutral rating and $6 price target on GameStop shares.
09/12/19
LOOP
09/12/19
NO CHANGE
Target $4
LOOP
Hold
Loop Capital sees 'steep uphill' for recovery at GameStop
Loop Capital analyst Anthony Chukumba kept his Hold rating and $4 price target on GameStop, saying its below-consensus Q2 earnings and a cut in FY19 guidance offers "no compelling reason" to become more constructive on the stock. The analyst believes that the new management still has a "steep uphill" to turn around the company's performance and expects the company to struggle until the next video game cycle begins in late 2020, with no assurances that it will cure its "current ills".
10/22/19
10/22/19
NO CHANGE

GameStop management to meet with Jefferies
Meeting to be held in New York on October 23 hosted by Jefferies.
09/11/19
BNCH
09/11/19
NO CHANGE
Target $3
BNCH
Sell
GameStop price target cut to $3 after 'Chernobyl experience' Q2 at Benchmark
Benchmark analyst Mike Hickey, who called GameStop's disappointing Q2 sales report and weak FY19 profitability guidance a "Chernobyl experience," does not expect investor sentiment to improve and sees "questionable valuations on current fundamentals" as "inherently flawed." He maintains a Sell rating on the stock following the company's earnings report and lowered his price target on GameStop shares to $3 from $5.
ADT ADT Inc.
$9.16

0.465 (5.35%)

05/13/19
05/13/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Deere (DE) and Titan Machinery (TITN) downgraded to Neutral from Outperform at Baird. 2. Boot Barn (BOOT) downgraded to Hold from Buy at Pivotal Research with analyst Mitch Kummetz saying he sees a less favorable risk/reward at current share levels heading into the company's results on May 16. He does not see enough room for upside to his estimates, mainly because he believes oil and gas employment is becoming a "diminishing tailwind." 3. Shopify (SHOP) downgraded to Neutral from Buy at Guggenheim with analyst Ken Wong saying he sees upside potential as limited given the stock's current valuation, which he notes has now passed previous peak levels. 4. ADT Inc. (ADT) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Toni Kaplan saying she has less confidence in the company's growth outlook following a recent AlphaWise survey conducted by the firm. 5. 51job (JOBS) downgraded to Neutral from Buy at Citi with analyst Alicia Yap saying she believes weakening operating metrics, such as a faster rate of decline for active employer count and slower rate of growth of ARPU, may be signals of challenges for online recruitment revenue growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/13/19
MSCO
05/13/19
DOWNGRADE
Target $7
MSCO
Equal Weight
ADT Inc. downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Toni Kaplan downgraded ADT Inc. (ADT) to Equal Weight from Overweight as she has less confidence in the company's growth outlook following a recent AlphaWise survey conducted by the firm. The survey showed homeowners seem as inclined to buy DIY systems as ADT systems, that more ADT customers switched to DIY providers than she would have expected and that measure of brand preference for Amazon's (AMZN) Ring and Google's (GOOG) Nest were higher than for ADT, Kaplan explains. Given that the survey leads her to fear ADT may find it difficult to defend its market share, Kaplan lowered her price target on the stock to $7 from $9.
03/15/19
IMPC
03/15/19
NO CHANGE
Target $12
IMPC
Outperform
ADT Inc. price target lowered to $12 from $15 at Imperial Capital
Imperial Capital analyst Jeff Kessler lowered his price target for ADT Inc. to $12 from $15 saying "heavy" investment translated to reduced free cash flow guidance for 2019. The analyst, however, sees continued revenue growth for ADT and maintains an Outperform rating on the shares.
03/12/19
SBSH
03/12/19
DOWNGRADE
Target $8.25
SBSH
Neutral
ADT Inc. downgraded to Neutral from Buy at Citi
Cit downgraded ADT Inc. to Neutral from Buy and lowered its price target for the shares to $8.25 from $13. The firm sees a less certain free cash flow trajectory following ADT's Q4 results.
FIT Fitbit
$6.78

-0.075 (-1.09%)

11/06/19
DADA
11/06/19
NO CHANGE
Target $20
DADA
Buy
Sonos rallies after DA Davidson calls 'natural acquisition target' for Apple
DA Davidson analyst Tom Forte reiterates a Buy rating on Sonos (SONO) with a $20 price target following Alphabet's (GOOG, GOOGL) acquisition of Fitbit (FIT). The stock in early trading is up 82c to $14.28. The analyst sees Sonos as the most likely company he covers to have its shares rally from either an improvement in investor perception or a takeover. Sonos is the "best house" on the "bad block" of hardware companies, and is "adjacent to the mansion on the neighboring block, Apple (AAPL)," Forte tells investors in a research note. Similar to Apple, Sonos makes products that are superior to the competition, has an eye for design, and boasts a premium brand that enables it to sell its products at higher prices than others, the analyst says. Further, Forte believes that similar to Fitbit not getting proper credit for its healthcare-related efforts, Sonos does not get credit for its superior technology and premium brand. As such, he sees Sonos as a "natural acquisition target for Apple." Furthermore, while less obvious than Apple, Amazon (AMZN) could acquire Sonos to advance its connected home efforts, according to Forte. The analyst also thinks the company could go private given the "lack of appreciation by Wall Street."
11/04/19
SBSH
11/04/19
UPGRADE
Target $7.35
SBSH
Neutral
Fitbit upgraded to Neutral from Sell at Citi
Citi analyst Jim Suva upgraded Fitbit (FIT) to Neutral from Sell with a price target of $7.35, up from $2.00. The analyst cites the takeover by Alphabet (GOOGL) for the upgrade to Neutral as he believes the acquisition will likely occur. He does not see any antitrust hurdles nor additional bidders.
11/01/19
MSCO
11/01/19
UPGRADE
Target $7.35
MSCO
Equal Weight
Fitbit upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley analyst Katy Huberty upgraded Fitbit (FIT) to Equal Weight from Underweight with a price target of $7.35, up from $3.20, after the company agreed to be acquired by Google (GOOGL).
11/04/19
DADA
11/04/19
DOWNGRADE
Target $7.35
DADA
Neutral
Fitbit downgraded to Neutral from Buy at DA Davidson
DA Davidson analyst Tom Forte downgraded Fitbit (FIT) to Neutral from Buy with a price target of $7.35, up from $5.75, after the company agreed to be acquired by Google (GOOGL). The analyst notes that while the deal may get some scrutiny from regulators, he is also encouraged that it is "finally" receiving "much deserved" attention for its healthcare-related business.
FTR Frontier Communications
$0.69

0.024 (3.61%)

02/19/19
RAJA
02/19/19
DOWNGRADE
RAJA
Market Perform
Frontier Communications downgraded to Market Perform at Raymond James
02/19/19
RAJA
02/19/19
DOWNGRADE
RAJA
Market Perform
Frontier Communications downgraded to Market Perform at Raymond James
Raymond James analyst Frank Louthan downgraded Frontier Communications (FTR) to Market Perform from Outperform saying the negative Windstream (WIN) ruling will have a negative impact from a trading perspective. Louthan said rural ILECs tend to trade as a group and are overly correlated with each other regardless of their results.
01/08/19
WELS
01/08/19
DOWNGRADE
Target $1.75
WELS
Underperform
Frontier downgraded to Underperform from Market Perform at Wells Fargo
Wells Fargo analyst Jennifer Fritzsche downgraded Frontier Communications (FTR) to Underperform and lowered her price target for the shares to $1.75 from $5.00. The analyst also downgraded the Rural Local Exchange Carrier sector to Underweight from Market Weight. Frontier has reportedly been working with an advisor on how it might handle upcoming debt maturities, Fritzsche tells investors in a research note. The debt seems to be pricing in a looming restructuring, which "could cause a scar on the RLEC industry," adds the analyst. Fritzsche remains concerned about Frontier's near term balance sheet obligations and believe "this is very much a debt story at this point."
06/20/19
SBSH
06/20/19
NO CHANGE
Target $1
SBSH
Sell
Frontier Communications price target lowered to $1.00 from $1.50 at Citi
Citi analyst Michael Rollins lowered his price target for Frontier Communications to $1.00 from $1.50 after incorporating a 25% risk of financial distress into his valuation analysis. While the recent asset sale was a "modest positive," recent press reports regarding informal discussions with bondholders suggests risk of financial distress is rising for Frontier, Rollins tells investors in a research note. Further, the analyst believes the appointment of two new board members who specialize in financial restructurings also increases the risk that Frontier may consider how to proactively restructure its balance sheet. He keeps a Sell rating on the shares.
JKS JinkoSolar
$16.93

-0.395 (-2.28%)

03/06/19
VERF
03/06/19
NO CHANGE
VERF
Sell
JinkoSolar a 'screaming short' given debt obligations, says Vertical Group
Vertical Group analyst Gordon Johnson said in an email that he believes JinkoSolar is a "screaming short" given that the company has not denied they are obligated for Jinko Power's "suspended" $299M bond offering, replying only that they "believe Jinko Power will be able to raise debt this year." In his email, Johnson added: "If they're wrong, which they were when Jinko Power tried to issue debt earlier this year, you're talking about an unknown debt liability the size of JKS' market cap (yes, you heard that right)." Johnson has a Sell rating on JinkoSolar shares.
10/07/19
GSCO
10/07/19
NO CHANGE
GSCO
Goldman says U.S. solar makers should benefit from end of bifacial exemption
Goldman Sachs analyst Brian Lee noted that the Office of the United States Trade Representative said it will withdraw a previously granted Section 201 tariff exemption for bifacial solar panels, which he sees removing a key potential overhang for solar panel pricing and U.S. competition and also believes was unexpected by most investors. Lee thinks U.S. solar manufacturers such as First Solar (FSLR) and SunPower (SPWR) are key beneficiaries of the news, while Chinese solar panel makers with bifacial capacity expansion plans, including JinkoSolar (JKS) and Canadian Solar (CSIQ), are most likely to be negatively impacted. Lee has Buy ratings on First Solar, SunPower and Canadian Solar and a Sell rating on JinkoSolar.
06/17/19
UBSW
06/17/19
DOWNGRADE
UBSW
Neutral
JinkoSolar downgraded to Neutral from Buy at UBS
UBS analyst Jon Windham downgraded JinkoSolar to Neutral from Buy.
06/18/19
UBSW
06/18/19
DOWNGRADE
Target $25
UBSW
Neutral
JinkoSolar downgraded to Neutral from Buy at UBS
UBS analyst Jon Windham downgraded JinkoSolar to Neutral from Buy while raising his price target for the shares to $25 from $22.
NKE Nike
$92.94

-0.4 (-0.43%)

11/25/19
BOFA
11/25/19
UPGRADE
Target $55
BOFA
Buy
Dick's Sporting upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Robert Ohmes upgraded Dick's Sporting (DKS) to Buy from Neutral with a $55 price target ahead of its Q3 results tomorrow, saying that at 11-times his expected FY21 earnings and given his upside same-store sales bias, the valuation on the stock is "compelling". The analyst believes that the company's digital and same-store sales momentum could accelerate further based on the success of its premium footwear selections as it receives "better lifestyle product assortment from Nike (NKE) and adidas (ADDYY), also noting that its apparel continues to be a strong category.
11/06/19
11/06/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Nike (NKE) and Foot Locker (FL) initiated with an Outperform at Raymond James while Lululemon (LULU) was initiated with a Strong Buy at Raymond James. 2. Momenta (MNTA) initiated with an Outperform at Wells Fargo. 3. Global Blood Therapeutics (GBT) initiated with a Hold at Canaccord. 4. Watford Holdings (WTRE) initiated with an Equal Weight at Morgan Stanley. 5. Pacira (PCRX) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/12/19
LEHM
11/12/19
INITIATION
Target $111
LEHM
Overweight
Nike initiated with an Overweight at Barclays
Barclays analyst Adrienne Yih initiated coverage of Nike with an Overweight rating and $111 price target. The analyst says the stock is her Top Pick in the sector given its potential to accelerate DTC sales, its long-range plan generating high-single-digit annual revenue growth and mid-teens earnings growth, as well as its continuous gross margin expansion on cost reduction measures.
11/13/19
NOMU
11/13/19
NO CHANGE
Target $42
NOMU
Neutral
Nike ending direct Amazon sales positive for Dick's, says Nomura Instinet
Nomura Instinet analyst Michael Baker says Nike's (NKE) decision to stop selling product directly to Amazon (AMZN), as reported this morning by Bloomberg, should be positive for Dick's Sporting Goods (DKS). Nike product will still be available on Amazon through its third-party market place, so the good for Dick's "is only modest," Baker tells investors in a research note titled "DKS Winning Online." The analyst believes Dick's is one of Nike's most valuable partners. The company accounts for about 6.6% of Nike's North American sales and 9.6% of its North American wholesale sales, and the penetration has been growing, contends Baker. This makes Dick's Nike's second-biggest wholesale partner, says the analyst, how keeps a Neutral rating on Dick's with a $42 price target.
TLRY Tilray
$20.78

-0.525 (-2.46%)

11/15/19
CANT
11/15/19
UPGRADE
CANT
Overweight
Cantor upgrades Aurora Cannabis to Overweight ahead of 2020 catalysts
Cantor Fitzgerald analyst Pablo Zuanic upgraded Aurora Cannabis to Overweight from Neutral with a price target of C$5.85, up from C$5.10. The analyst does not expect a worse quarter for the group than the September quarter. And even though little may change in the December quarter, positive catalysts align in 2020, Zuanic tells investors in a research note. Further, based on his read of the quarter for the group, he estimates Aurora is "overall in better shape than peers." The analyst highlights the company's "stable" pricing, "best-in-class" gross margins of 56%, which he notes are near three-times Tilray's (TLRY), and no signs of provisions for rebates and returns.
11/14/19
MKMP
11/14/19
NO CHANGE
Target $26
MKMP
Neutral
Tilray price target lowered to $26 from $34 at MKM Partners
MKM Partners analyst Bill Kirk lowered his price target on Tilray to $26 and kept his Neutral rating after its mixed Q3 results, with revenue just above consensus and EBITDA missing expectations. The analyst notes that other companies in the cannabis space missed on both top line and profitability, stating that until these companies curtail spending or the pricing improves, near-term profitability for Tilray is also difficult to model. Kirk adds that lower price point products may be "the only way to compete" with the illicit market, but make achieving profitability even more difficult.
11/13/19
BNCH
11/13/19
NO CHANGE
Target $40
BNCH
Buy
Tilray price target lowered to $40 from $80 at Benchmark
Benchmark analyst Mike Hickey halved his price target for Tilray shares to $40 from $80 after the company's "mixed" Q3 performance that included slightly better than consensus sales and profitability that "again disappointed." However, he notes that gross margins expanded again sequentially and noted that Tilray said it sees reaching adjusted EBITDA profitability in the fiscal fourth quarter of FY20, when the consensus is still calling for a loss. He remains cautious on the Canadian regulatory environment and expects on-going near term supply and distribution constraints, but keeps a Buy rating on Tilray shares.
11/05/19
BOFA
11/05/19
NO CHANGE
BOFA
BofA says Mexico cannabis legalization 'still in play' in 2020 after extension
BofA Merrill Lynch analyst Christopher Carey noted that Mexico's Supreme Court has granted an extension until April 30, 2020 for Congress to legalize all forms of cannabis, writing in its decision that considering the complexity of the issue it grants the extension "exceptionally and for one time only." He views this as an important development for the industry since, in addition to opening a potentially large market, it will put even more pressure on U.S. federal action as the country will potentially "place the US between 2 of only 3 countries in the world to have legalized cannabis for recreational use." 9% of Mexico's population of 131M is estimated to have consumed cannabis in 2018 and the legal market could be worth $1B by 2024, according to BDS Analytics, noted Carey. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), Tilray (TLRY) and Trulieve Cannabis (TCNNF).
IYR DJ US Real Estate Index Fund
$92.04

0.33 (0.36%)

TODAY'S FREE FLY STORIES

IFF

International Flavors

$142.03

0.21 (0.15%)

, DD

DuPont

$63.60

1.6 (2.58%)

13:47
12/08/19
12/08
13:47
12/08/19
13:47
Periodicals
International Flavors in talks to buy DuPont nutrition unit, Bloomberg reports »

International Flavors…

IFF

International Flavors

$142.03

0.21 (0.15%)

DD

DuPont

$63.60

1.6 (2.58%)

KRYAY

Kerry Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHWRF

China Tower

$0.00

(0.00%)

13:40
12/08/19
12/08
13:40
12/08/19
13:40
Upgrade
China Tower rating change  »

China Tower upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

13:37
12/08/19
12/08
13:37
12/08/19
13:37
Recommendations
Principia Biopharma analyst commentary  »

Principia shares have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DY

Dycom

$50.93

0.495 (0.98%)

12:48
12/08/19
12/08
12:48
12/08/19
12:48
Syndicate
Dycom withdraws senior notes offering due to market conditions »

Dycom Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

IMV

IMV Inc.

$2.92

0.07 (2.46%)

12:30
12/08/19
12/08
12:30
12/08/19
12:30
Hot Stocks
IMV announces updated results from Phase 2 study of DPX-Survivac »

IMV Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KURA

Kura Oncology

$15.67

0.48 (3.16%)

12:27
12/08/19
12/08
12:27
12/08/19
12:27
Hot Stocks
Kura Oncology announces updates for lead drug candidate tipifarnib »

Kura Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

PTLA

Portola Pharmaceuticals

$29.22

0.86 (3.03%)

12:24
12/08/19
12/08
12:24
12/08/19
12:24
Hot Stocks
Portola presents interim results from Phase 2a study of cerdulatinib »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

11:25
12/08/19
12/08
11:25
12/08/19
11:25
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

10:49
12/08/19
12/08
10:49
12/08/19
10:49
Hot Stocks
Fate Therapeutics announces vivo preclinical data for FT596 »

Fate Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

10:04
12/08/19
12/08
10:04
12/08/19
10:04
Hot Stocks
Stoke Therapeutics presents STK-001 preclinical data in Dravet syndrome »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

09:25
12/08/19
12/08
09:25
12/08/19
09:25
Hot Stocks
Autolus announces new data highlighting progress on AUTO3 »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

09:22
12/08/19
12/08
09:22
12/08/19
09:22
Hot Stocks
Agios says proof-of-concept has been established for mitapivat »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

ZIOP

Ziopharm

$5.16

0.06 (1.18%)

09:20
12/08/19
12/08
09:20
12/08/19
09:20
Hot Stocks
Ziopharm reports pre-clinical data of Rapid Personalized Manufacture »

Ziopharm Oncology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

TGTX

TG Therapeutics

$7.11

-0.57 (-7.42%)

09:18
12/08/19
12/08
09:18
12/08/19
09:18
Hot Stocks
TG Therapeutics reports triple therapy data from Phase I/II study of ublitux »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:16
12/08/19
12/08
09:16
12/08/19
09:16
Hot Stocks
Karyopharm says four posters will be presented at ASH »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPHA

Innate Pharma

$6.30

(0.00%)

09:13
12/08/19
12/08
09:13
12/08/19
09:13
Hot Stocks
Innate Pharma reports long-term data from Phase III trial of Lumoxiti »

Innate Pharma shared new,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$372.26

4.02 (1.09%)

09:11
12/08/19
12/08
09:11
12/08/19
09:11
Hot Stocks
Regeneron reports initial data for REGN5458 in myeloma patients »

Regeneron Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:09
12/08/19
12/08
09:09
12/08/19
09:09
Hot Stocks
Blueprint reports 77% overall response rate in 48 patients from Explorer trial »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:06
12/08/19
12/08
09:06
12/08/19
09:06
Hot Stocks
Blueprint announces initial data from Phase 2 Pioneer trial in mastocytosis »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

PCG

PG&E

$9.65

-0.13 (-1.33%)

08:12
12/08/19
12/08
08:12
12/08/19
08:12
Periodicals
PG&E settlement threatens bondholders plan, WSJ reports »

PG&E's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

SYRS

Syros Pharmaceuticals

$4.60

-0.02 (-0.43%)

08:08
12/08/19
12/08
08:08
12/08/19
08:08
Hot Stocks
Syros announces fetal hemoglobin repressor using gene control platform »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:06
12/08/19
12/08
08:06
12/08/19
08:06
Hot Stocks
AbbVie says post-hoc analysis supports benefit of venetoclax in combination »

AbbVie presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

08:03
12/08/19
12/08
08:03
12/08/19
08:03
Hot Stocks
Genentech reports data from two Phase III Venclexta studies in leukemia »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

ORTX

Orchard Therapeutics

$11.85

0.37 (3.22%)

07:59
12/08/19
12/08
07:59
12/08/19
07:59
Hot Stocks
Orchard to present data from multiple programs at ASH meeting »

Orchard Therapeutics said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

06:55
12/08/19
12/08
06:55
12/08/19
06:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.